Advertisement


Tara B. Sanft, MD, on How Diet and Exercise May Affect Completion of Chemotherapy for Breast Cancer

2022 ASCO Annual Meeting

Advertisement

Tara B. Sanft, MD, of Yale University, discusses the results of the LEANer study (Lifestyle, Exercise, and Nutrition Early After Diagnosis) in women with breast cancer. It showed that patients with newly diagnosed disease who were just starting chemotherapy could improve physical activity and diet quality. While both groups had high rates of treatment completion, women in the intervention who exercised at or above the recommended levels did better in terms of treatment completion, with fewer dose reductions and delays (Abstract 12007).

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We know completing chemotherapy as prescribed is important for cancer outcomes. We also know that adopting healthy diet and exercise is important, both for cancer prevention and, in certain cancers, can improve cancer-related survival. The healthy diet and exercise guidelines include eating a predominantly plant-based diet and exercising with moderate intensity exercise at least 150 minutes per week, and performing two strength training sessions per week. Our study, the Lifestyle, Exercise, and Nutrition Study, randomized women who were not meeting these guidelines to a healthy diet and exercise intervention based on the Diabetes Prevention Protocol and adapted using the cancer-related guidelines as well versus usual care, which is referral to our survivorship clinic and dieticians and exercise programs at request by the patient. Our primary outcome was looking at the relative dose intensity, or the actual amount of chemotherapy received compared to that which was prescribed. The intervention group received a year-long intervention of 16 sessions administered by a registered dietician who was certified, specialized in oncology, and also had exercise counseling training. The control group were followed at baseline post-chemotherapy. What we found was that both groups completed chemotherapy at very high rates, with both groups approaching about 93% completion rates. This is higher than what we had found in the literature before. We also found that the number of dose delays and reductions were similar between the two groups. When we looked at the intervention group, in particular, and we looked at if they were meeting the actual recommendations, that is 150 minutes per week and a high consumption of fruits and vegetables, we found that women who were able to meet these guidelines or exceeded them, did have higher completion rates compared to those who didn't quite make those guidelines. So in summary, the women who made the highest number of changes or adhered the best did have better relative dose intensity and fewer dose reductions and delays. But when we took the entire intervention group and compared them to usual care, we did not find a statistically significant difference. In summary, both groups completed their chemotherapy as prescribed most of the time, and the intervention group significantly improved both their diet and physical activity during the course of the intervention. Those who were able to adopt the exercise and diet recommendations the best did have significant improvements in their completion rates and fewer dose reductions and delays compared to those who didn't adopt it as well.

Related Videos

Bladder Cancer

Karim Chamie, MD, on Bladder Cancer: Final Results on N-803 and Bacillus Calmette-Guérin

Karim Chamie, MD, of the University of California, Los Angeles, discusses final clinical results on combining the superagonist N-803 with bacillus Calmette-Guérin (BCG) in patients whose carcinoma in situ and high-grade non–muscle-invasive bladder cancers are unresponsive to BCG alone. Of note, cystectomy was avoided in more than 90% of patients with 2 years of follow-up (Abstract 4508).

Breast Cancer

Ann H. Partridge, MD, MPH, and Véronique Diéras, MD, on the Future of Cytotoxic Therapy: Antibody-Drug Conjugates?

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Véronique Diéras, MD, of the Centre Eugène Marquis, discuss the many challenges posed by next-generation antibody-drug conjugates (ADCs). They include side effects such as hematotoxicity, gastrointestinal toxicities, and interstitial lung disease; tumor targeting and payload release; drug resistance; and the urgent need to understand ADCs’ mechanisms of action to better sequence and combine drugs.

Colorectal Cancer
Genomics/Genetics

Michael J. Overman, MD, and Smitha Krishnamurthi, MD, on RAS Wild-Type Metastatic Colorectal Cancer: Refining Treatment Strategy

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Smitha Krishnamurthi, MD, of the Cleveland Clinic, review three abstracts, all of which enrolled patients with newly diagnosed RAS and BRAF wild-type metastatic colorectal cancer with left-sided primary tumors. The discussion centers on what the study results indicate about the use of an EGFR therapy and weighing the risk to quality of life from rash, in particular (Abstracts LBA3503, LBA3504, LBA3505).

Gynecologic Cancers
Immunotherapy

Ursula A. Matulonis, MD, and Ignace Vergote, MD, PhD, on Cervical Cancer: Interim Results on Tisotumab Vedotin-tftv Plus Pembrolizumab

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion cohort evaluating first-line tisotumab vedotin-tftv plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Data on the combination showed durable antitumor activity with a manageable safety profile (Abstract 5507).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on Prostate Cancer: Updated Overall Survival Outcomes With Enzalutamide

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Ian D. Davis, PhD, MBBS, of Monash University and Eastern Health, discuss the latest findings from ANZUP Cancer Trials Group’s ENZAMET cooperative group trial of enzalutamide in patients with metastatic hormone-sensitive prostate cancer. The results corroborate the benefit of enzalutamide with improved overall survival, and involve some exploratory subgroup analyses (Abstract LBA5004).

Advertisement

Advertisement




Advertisement